Therakos receives US approval for rare lymphoma therapy
This article was originally published in Scrip
Executive Summary
Therakos's (Johnson & Johnson) THERAKOS CELLEX Photopheresis System has been approved by the US FDA for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that are unresponsive to other forms of treatment.